Roche: The Hanover specialty growth to rebound after moderating to 3.4% in Q3
The Hanover’s CEO has expressed confidence that growth in his company’s specialty business will rebound in the fourth quarter after moderating in Q3 because of profitability improvement initiatives in its programs segment.
If you are a subscriber, please sign back in to read this article
If you are not currently a subscriber please see contact details below